On Oct. 18, 2016, NCATS announced a new funding opportunity for the next phase of the Tissue Chip for Drug Screening program. For the Tissue Chips for Disease Modeling and Efficacy Testing initiative, the Center and its collaborators plan to commit an estimated total of $13.5 million in fiscal year 2017 for 10 to 12 awards.
The new support will enable researchers to create models of human disease using tissue chip technology for testing the effectiveness of candidate drugs. Failure to demonstrate efficacy accounts for approximately 65 percent of drug failures during clinical trials. Ultimately, these disease models will help scientists to better assess biomarkers, bioavailability, efficacy and toxicity of candidate therapeutics prior to entry into clinical trials.
NCATS funds its Tissue Chip for Drug Screening program through the Cures Acceleration Network.
NIH Institutes, Centers and Offices also contributing funding, expertise and resources include the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Dental and Craniofacial Research, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Environmental Health Sciences, the National Institute of Neurological Disorders and Stroke, and the Office of Research on Women’s Health.
Learn more about RFA-TR-16-017 and other Tissue Chip for Drug Screening funding opportunities.
Posted October 2016